Vigabatrin

Vigabatrin
Clinical data
Pronunciation	/vaɪˈɡæbətrɪn/; vy-GAB-ə-trin
Trade names	Sabril, Vigadrone
Other names	γ-Vinyl-GABA
AHFS/Drugs.com	Monograph
MedlinePlus	a610016
Pregnancy; category	AU: D;
Routes of; administration	By mouth
ATC code	N03AG04 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); BR: Class C1 (Other controlled substances); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	80–90%
Protein binding	0%
Metabolism	not metabolized
Elimination half-life	5–8 hours in young adults, 12–13 hours in the elderly.
Excretion	Kidney
Identifiers
	IUPAC name (RS)-4-aminohex-5-enoic acid;
CAS Number	68506-86-5 ;
PubChem CID	5665;
IUPHAR/BPS	4821;
DrugBank	DB01080 ;
ChemSpider	5463 ;
UNII	GR120KRT6K;
KEGG	D00535 ;
ChEMBL	ChEMBL89598 ;
CompTox Dashboard (EPA)	DTXSID4041153 ;
ECHA InfoCard	100.165.122
Chemical and physical data
Formula	C6H11NO2
Molar mass	129.159 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	171 to 177 °C (340 to 351 °F)
	SMILES O=C(O)CCC(\C=C)N;
	InChI InChI=1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9) ; Key:PJDFLNIOAUIZSL-UHFFFAOYSA-N ;
	(verify)

Vigabatrin, sold under the brand name Sabril, is a medication used to treat epilepsy. It became available as a generic medication in 2019.

It works by inhibiting the breakdown of γ-aminobutyric acid (GABA). It is also known as γ-vinyl-GABA, and is a structural analogue of GABA, but does not bind to GABA receptors.

Vigabatrin is generally used only in cases of treatment-resistant epilepsy due to the risk of permanent vision loss.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.